The Role of N-methyladenosine Modification in Acute and Chronic Kidney Diseases

Overview

Journal Mol Med

Publisher Biomed Central

Specialties General Medicine
Molecular Biology

Date 2023 Dec 8

PMID 38066436

Authors

Saiqi Qi

Jie Song

Linjun Chen

Huachun Weng

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (m6A) modification is a kind of RNA modification in which methylation occurs at the sixth N position in adenosine in RNA, which can occur in various RNAs such as mRNAs, lncRNAs and miRNAs. This is one of the most prominent and frequent posttranscriptional modifications within organisms and has been shown to function dynamically and reversibly in a variety of ways, including splicing, export, attenuation and translation initiation efficiency to regulate RNA expression. There are three main enzymes associated with m6A modification: writers, readers and erasers. Increasing evidence has shown that m6A modification is associated with the onset and development of kidney disease. In this article, we address the important physiological and pathological roles of m6A modification in kidney diseases (uremia, ischemia-reperfusion kidney injury, drug-induced kidney injury, and diabetic nephropathy) and its molecular mechanisms to provide reference for the diagnosis and clinical management of kidney diseases.

Citing Articles

Methyltransferase-like 3 represents a prospective target for the diagnosis and treatment of kidney diseases.

Song B, Wu X, Zeng Y Hum Genomics. 2024; 18(1):125.

PMID: 39538346 PMC: 11562609. DOI: 10.1186/s40246-024-00692-8.

References

Sun Q, Geng H, Zhao M, Li Y, Chen X, Sha Q . FTO-mediated m A modification of SOCS1 mRNA promotes the progression of diabetic kidney disease. Clin Transl Med. 2022; 12(6):e942. PMC: 9217105. DOI: 10.1002/ctm2.942. View

Nasr S, Markowitz G, Stokes M, Said S, Valeri A, DAgati V . Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature. Medicine (Baltimore). 2008; 87(1):21-32. DOI: 10.1097/md.0b013e318161b0fc. View

Wang J, Wang F, Ke J, Li Z, Xu C, Yang Q . Inhibition of attenuates renal injury and inflammation by alleviating m6A modifications via IGF2BP2-dependent mechanisms. Sci Transl Med. 2022; 14(640):eabk2709. DOI: 10.1126/scitranslmed.abk2709. View

Bagshaw S, Laupland K, Doig C, Mortis G, Fick G, Mucenski M . Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care. 2005; 9(6):R700-9. PMC: 1414056. DOI: 10.1186/cc3879. View

Zhou P, Wu M, Ye C, Xu Q, Wang L . Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated mA abrogation in RNA. J Biol Chem. 2019; 294(45):16908-16917. PMC: 6851328. DOI: 10.1074/jbc.RA119.011009. View

Yang C, Wang H, Zhao X, Matsushita K, Coresh J, Zhang L . CKD in China: Evolving Spectrum and Public Health Implications. Am J Kidney Dis. 2019; 76(2):258-264. DOI: 10.1053/j.ajkd.2019.05.032. View

Mao Y, Jiang F, Xu X, Zhou L, Jin R, Zhuang L . Inhibition of IGF2BP1 attenuates renal injury and inflammation by alleviating m6A modifications and E2F1/MIF pathway. Int J Biol Sci. 2023; 19(2):593-609. PMC: 9830505. DOI: 10.7150/ijbs.78348. View

Kaur R, Singh R . Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications. Life Sci. 2022; 311(Pt B):121148. DOI: 10.1016/j.lfs.2022.121148. View

Hammad F . The long-term renal effects of short periods of unilateral ureteral obstruction. Int J Physiol Pathophysiol Pharmacol. 2022; 14(2):60-72. PMC: 9123473. View

10.

Xu Y, Yuan X, Wu J, Chen R, Xia L, Zhang M . The N6-methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1. J Cell Biochem. 2019; 121(1):524-533. DOI: 10.1002/jcb.29258. View

11.

Li X, Jiang Y, Sun X, Wu Y, Chen Z . METTL3 is required for maintaining β-cell function. Metabolism. 2021; 116:154702. DOI: 10.1016/j.metabol.2021.154702. View

12.

SCHAFER K . RNA synthesis and processing reactions in a subcellular system from mouse L cells. Hoppe Seylers Z Physiol Chem. 1982; 363(1):33-43. DOI: 10.1515/bchm2.1982.363.1.33. View

13.

Liu B, Tu Y, Ni G, Yan J, Yue L, Li Z . Total Flavones of Ameliorates Podocyte Pyroptosis and Injury in High Glucose Conditions by Targeting METTL3-Dependent mA Modification-Mediated NLRP3-Inflammasome Activation and PTEN/PI3K/Akt Signaling. Front Pharmacol. 2021; 12:667644. PMC: 8319635. DOI: 10.3389/fphar.2021.667644. View

14.

Zhao H, Pan S, Duan J, Liu F, Li G, Liu D . Integrative Analysis of mA Regulator-Mediated RNA Methylation Modification Patterns and Immune Characteristics in Lupus Nephritis. Front Cell Dev Biol. 2021; 9:724837. PMC: 8454410. DOI: 10.3389/fcell.2021.724837. View

15.

Shen J, Wang W, Shao X, Wu J, Li S, Che X . Integrated Analysis of m6A Methylome in Cisplatin-Induced Acute Kidney Injury and Berberine Alleviation in Mouse. Front Genet. 2020; 11:584460. PMC: 7718005. DOI: 10.3389/fgene.2020.584460. View

16.

Liu B, Ao S, Tan F, Ma W, Liu H, Liang H . Transcriptomic analysis and laboratory experiments reveal potential critical genes and regulatory mechanisms in sepsis-associated acute kidney injury. Ann Transl Med. 2022; 10(13):737. PMC: 9358506. DOI: 10.21037/atm-22-845. View

17.

Wertheim H, Van Nguyen K, Hara G, Gelband H, Laxminarayan R, Mouton J . Global survey of polymyxin use: A call for international guidelines. J Glob Antimicrob Resist. 2014; 1(3):131-134. PMC: 3991322. DOI: 10.1016/j.jgar.2013.03.012. View

18.

Li X, Li Y, Wang Y, He X . The mA demethylase FTO promotes renal epithelial-mesenchymal transition by reducing the mA modification of lncRNA GAS5. Cytokine. 2022; 159:156000. DOI: 10.1016/j.cyto.2022.156000. View

19.

Hu J, Lieb J, Sancar A, Adar S . Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proc Natl Acad Sci U S A. 2016; 113(41):11507-11512. PMC: 5068337. DOI: 10.1073/pnas.1614430113. View

20.

Kopp J, Anders H, Susztak K, Podesta M, Remuzzi G, Hildebrandt F . Podocytopathies. Nat Rev Dis Primers. 2020; 6(1):68. PMC: 8162925. DOI: 10.1038/s41572-020-0196-7. View